Showing results (381-390 of 461) with videos related to

Sort By:
Pageof 47
Blood Cancer Journal|May 8, 2020
The role of bone marrow biopsy in patients with plasma cell disorders: should all patients with a monoclonal protein be biopsied?M Hasib Sidiqi, Mohammed Aljama, Shaji K Kumar, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 3, 2020
Implications of MYC Rearrangements in Newly Diagnosed Multiple MyelomaNadine Abdallah, Linda B Baughn, S Vincent Rajkumar, et al.
Clinical Lymphoma, Myeloma & Leukemia|November 6, 2019
Cytogenetic Features and Clinical Outcomes of Patients With Non-secretory Multiple Myeloma in the Era of Novel Agent Induction TherapyBharat Nandakumar, Shaji K Kumar, Angela Dispenzieri, et al.
Mayo Clinic Proceedings|March 6, 2021
Clinical Characteristics and Outcomes of Patients With Primary Plasma Cell Leukemia in the Era of Novel Agent TherapyBharat Nandakumar, Shaji K Kumar, Angela Dispenzieri, et al.
American Journal of Hematology|August 12, 2017
Efficacy of daratumumab-based therapies in patients with relapsed, refractory multiple myeloma treated outside of clinical trialsArjun Lakshman, Jithma P Abeykoon, Shaji K Kumar, et al.
Kidney International|July 27, 2020
A study from The Mayo Clinic evaluated long-term outcomes of kidney transplantation in patients with immunoglobulin light chain amyloidosisCihan Heybeli, Andrew Bentall, Jiqiu Wen, et al.
Blood Cancer Journal|August 13, 2020
Cytogenetic abnormalities in multiple myeloma: association with disease characteristics and treatment responseNadine Abdallah, S Vincent Rajkumar, Patricia Greipp, et al.
American Journal of Hematology|April 5, 2019
Prognostic value of minimal residual disease and polyclonal plasma cells in myeloma patients achieving a complete response to therapyMarcella A Tschautscher, Dragan Jevremovic, Vincent Rajkumar, et al.
Leukemia|March 28, 2018
Depth of organ response in AL amyloidosis is associated with improved survival: grading the organ response criteriaEli Muchtar, Angela Dispenzieri, Nelson Leung, et al.
Blood Cancer Journal|August 1, 2018
Phase 1/2 trial of ixazomib, cyclophosphamide and dexamethasone in patients with previously untreated symptomatic multiple myelomaShaji K Kumar, Francis K Buadi, Betsy LaPlant, et al.
Pageof 47